- Home
- MBRX vs AYTU Comparison
MBRX vs AYTU Comparison
Compare MBRX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | AYTU |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 20.5M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBRX | AYTU |
|---|---|---|
| Price | $7.24 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $125.00 | $9.17 |
| AVG Volume (30 Days) | ★ 105.9K | 47.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.01 | $0.95 |
| 52 Week High | $91.25 | $2.82 |
Technical Indicators
Market Signals| Indicator | MBRX | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 89.96 | 56.07 |
| Support Level | $0.26 | $2.05 |
| Resistance Level | $7.75 | $2.18 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | 0.83 | 0.02 |
| Stochastic Oscillator | 93.19 | 93.17 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.